Vancomycin - info-atbvac

info-atbvac > Vancomycin

Continuous infusion of vancomycin is less toxic than intermittent infusion. It’s time to act. ( Kang CK, et al. )

Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin.

30 jan | Dr Jean-Pierre Bru

Numerous consensus guidelines recommend intermittent-infusion vancomycin (IIV) at 15–20 mg/kg every 8–12 h in patients with complicated Staphylococcus aureus infections, … Suite

Dose addition of intravenous metronidazole to oral vancomycin improve outcomes in Clostridioides difficile infection? ( Wang Y. et al. )

Dose addition of intravenous metronidazole to oral vancomycin improve outcomes in Clostridioides difficile infection?

07 jan | Dr Jean-Pierre Bru

Dual therapy with vancomycin (oral/nasogastric tube/rectal instillation) and intravenous (IV) metronidazole is recommended only for the treatment of severe CDI … Suite

Can bacteremia due to glycopeptide-susceptible Enterococcus faecium be treated with linezolid? ( Echeverria-Esnal D. et al. )

Linezolid versus glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteremia: A propensity-score matched comparative study.

17 déc | Dr Philippe Lesprit

Vancomycin is the first-line treatment of glycopeptide (GP)-susceptible E. faecium (GSEF)-bloodstream infections (BSI) except for the rare amoxicillin-sensitive strains. GP … Suite

A robust test to detect the risk of DRESS syndrome under vancomycin. ( Konvinse KC. et al. )

HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms

04 nov | Pr Pierre Tattevin

Vancomycin has been associated with DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), a rare but potentially fatal hypersensitivity … Suite